Functional analysis of natural PCSK 9 mutants in modern and archaic humans

Novel strategies to target PCSK9: beyond monoclonal antibodies

(2019) Nabil G Seidah et al.   CARDIOVASCULAR RESEARCH

The Elusive Inhibitory Function of the Acidic N-Terminal Segment of the Prodomain of PCSK9: The Plot Thickens

(2019) Nabil G. Seidah   JOURNAL OF MOLECULAR BIOLOGY

New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia

(2018) Sandy Elbitar et al.   Scientific Reports

Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia

(2018) Michael A. Iacocca et al.   CANADIAN JOURNAL OF CARDIOLOGY

Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake

(2018) Adri M. Galvan et al.   JOURNAL OF LIPID RESEARCH

Inferring Past Environments from Ancient Epigenomes

(2017) David Gokhman et al.   MOLECULAR BIOLOGY AND EVOLUTION

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor

(2017) Camilla Gustafsen et al.   Nature Communications

The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation

(2016) Delia Susan-Resiga et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genome-Wide DNA Methylation Analysis and Epigenetic Variations Associated with Congenital Aortic Valve Stenosis (AVS)

(2016) Uppala Radhakrishna et al.   PLoS One

Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis

(2016) Dhruva J. Dwivedi et al.   SHOCK

The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance

(2015) Keith R. Walley et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening

(2015) Siddharth Singh et al.   Current Atherosclerosis Reports

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

(2013) Evan A. Stein et al.   CIRCULATION

The genetic spectrum of familial hypercholesterolemia in Pakistan

(2013) Waqas Ahmed et al.   CLINICA CHIMICA ACTA

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies

(2013) Nabil G. Seidah   CURRENT PHARMACEUTICAL DESIGN

Furin Is the Primaryin VivoConvertase of Angiopoietin-like 3 and Endothelial Lipase in Hepatocytes

(2013) Rachid Essalmani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The complete genome sequence of a Neanderthal from the Altai Mountains

(2013) Kay Prüfer et al.   NATURE

Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients

(2012) Afef Slimani et al.   ATHEROSCLEROSIS

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

(2012) Marianne Abifadel et al.   ATHEROSCLEROSIS

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

A High-Coverage Genome Sequence from an Archaic Denisovan Individual

(2012) M. Meyer et al.   SCIENCE

Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture

(2011) J. Mayne et al.   CLINICAL CHEMISTRY

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

(2010) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

(2009) Bertrand Cariou et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

(2009) Steve Poirier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A new method for measurement of total plasma PCSK9: clinical applications

(2009) Geneviève Dubuc et al.   JOURNAL OF LIPID RESEARCH

SeaView Version 4: A Multiplatform Graphical User Interface for Sequence Alignment and Phylogenetic Tree Building

(2009) M. Gouy et al.   MOLECULAR BIOLOGY AND EVOLUTION

Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion

(2008) Jamie Cameron et al.   FEBS Journal

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population

(2007) Yasuko Miyake et al.   ATHEROSCLEROSIS